Art. -Nr.: HY-B0715

Pentoxifylline

(Synonyms: BL-191; PTX; Oxpentifylline)

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 6493-05-6
Formel: C₁₃H₁₈N₄O₃
Molecular Weight:278.31

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pentoxifylline Chemical Structure

CAS. Nr.: 6493-05-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

PDE^[1]

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen :

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	IC₅₀	247 μM Compound: Pentoxifylline	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 4 hrs by ELISA Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production after 4 hrs by ELISA	[PMID: 11000020]

In Vitro

Pentoxifylline (0.1-50 mM; 24-48 hours) inhibits cell proliferation in a dose-dependent manner^[3].
Pentoxifylline (0.5 mM; 12-36 hours) increases apoptosis and decreases autophagy levels in MDA-MB-231 cells^[3].
Pentoxifylline (0.5 mM; 12-36 hours) induces autophagy in MDA-MB-231 cells^[3].
Pentoxifylline (0.5 mM; 24-48 hours) blocks cell cycle at the G0/G1 phase^[3].
Pentoxifylline results in high LC3-II/LC3-ratio^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[3]

Cell Line:

MDA-MB-231 cells
Concentration:

0.1 mM, 1 mM, 5 mM , 10 mM, 50 mM
Incubation Time:

24 hours, 48 hours
Result:

Inhibited cell proliferation in a dose-dependent manner.

Apoptosis Analysis^[3]

Cell Line:

MDA-MB-231 cells
Concentration:

0.5 mM
Incubation Time:

12 hours, 24 hours, 36 hours
Result:

Induced apoptosis.

Cell Autophagy Assay^[3]

Cell Line:

MDA-MB-231 cells
Concentration:

0.5 mM
Incubation Time:

24 hours, 48 hours
Result:

Induced approximately 20-28% of cell autophagy.

Cell Cycle Analysis^[3]

Cell Line:

MDA-MB-231 cells
Concentration:

0.5 mM
Incubation Time:

24 hours, 48 hours
Result:

Induced G0/G1 phase arrest.

Western Blot Analysis^[3]

Cell Line:

MDA-MB-231 cells
Concentration:

0.5 mM
Incubation Time:

24 hours, 48 hours
Result:

Induced high LC3-II/LC3-ratio.

In Vivo

Pentoxifylline (200 mg/kg; i.p.) has a protective effect on rats with transient global ischemia and reduces cognitive impairment^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult male Wistar rats 12-13-weeks-old (250-300 g)^[4]
Dosage:

200 mg/kg
Administration:

Intraperitoneal injection, at 1hr before and 3 hr after ischemia
Result:

Significantly improved the spatial memory and effects were significant different from those of sham-operated and vehicle groups.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 6493-05-6
Appearance Solid
Molecular Weight 278.31
Formel C₁₃H₁₈N₄O₃
Color White to off-white
SMILES

O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O
Synonyms

BL-191; PTX; Oxpentifylline
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (13)

All

Sort by:

Journal Impact Factor

Cell

Elucidating pathway-selective biased CCKBR agonism for Alzheimer's disease treatment. [Abstract]

2026 Jan 22;189(2):640-658.e22. PMID: 41270732
Mol Cancer

An EHMT2/NFYA-ALDH2 signaling axis modulates the RAF pathway to regulate paclitaxel resistance in lung cancer. [Abstract]

2022 Apr 27;21(1):106. PMID: 35477569
ACS Nano

Extracellular Vesicle-Mediated Precision Delivery of Paclitaxel Activates Mitophagy to Promote Repair after Spinal Cord Injury. [Abstract]

2026 Mar 24;20(11):9387-9406. PMID: 41773788
J Adv Res

Inflammation-driven biomimetic nano-polyphenol drug delivery system alleviates severe acute pancreatitis by inhibiting macrophage PANoptosis and pancreatic enzymes oversecretion. [Abstract]

2025 Apr 8:S2090-1232(25)00225-5. PMID: 40210149
Sci Immunol

Citraconate preserves T cell stemness and antitumor immunity. [Abstract]

2026 May;11(119):eadz0348. PMID: 42066062
Eur J Pharmacol

Pentoxifylline treats Aspergillus fumigatus keratitis by reducing fungal burden and suppressing corneal inflammation. [Abstract]

2023 Apr 15:945:175607. PMID: 36822458
J Integr Agric

2023 Feb 24.
Microchem J

2026 May 1.
Sci Rep

Pharmacological alternatives to oxytetracycline as potential treatment of flexural limb deformities in foals: a preliminary in vitro cell viability and proliferation study. [Abstract]

2025 May 6;15(1):15762. PMID: 40328831
Oncol Rep

Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer. [Abstract]

2021 Mar;45(3):1306-1314. PMID: 33650669
J Cancer Res Clin Oncol

YAP inhibitor verteporfin suppresses tumor angiogenesis and overcomes chemoresistance in esophageal squamous cell carcinoma. [Abstract]

2023 Aug;149(10):7703-7716. PMID: 37000262
Prostate

Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis. [Abstract]

2019 May;79(6):647-656. PMID: 30714183
Research Square Print

2023 Feb 14.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (359.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 93.3 mg/mL (335.24 mM; Need ultrasonic and warming)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5931 mL

17.9656 mL

35.9312 mL

5 mM

0.7186 mL

3.5931 mL

7.1862 mL

10 mM

0.3593 mL

1.7966 mL

3.5931 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 110 mg/mL (395.24 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5(4): 510–516. [Content Brief]

[2]. A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34(1):50-97. [Content Brief]

[3]. Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52(4):1246-1254. [Content Brief]

[4]. Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15(5): 1083-1090. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.5931 mL	17.9656 mL	35.9312 mL	89.8279 mL
	5 mM	0.7186 mL	3.5931 mL	7.1862 mL	17.9656 mL
	10 mM	0.3593 mL	1.7966 mL	3.5931 mL	8.9828 mL
	15 mM	0.2395 mL	1.1977 mL	2.3954 mL	5.9885 mL
	20 mM	0.1797 mL	0.8983 mL	1.7966 mL	4.4914 mL
	25 mM	0.1437 mL	0.7186 mL	1.4372 mL	3.5931 mL
	30 mM	0.1198 mL	0.5989 mL	1.1977 mL	2.9943 mL
	40 mM	0.0898 mL	0.4491 mL	0.8983 mL	2.2457 mL
	50 mM	0.0719 mL	0.3593 mL	0.7186 mL	1.7966 mL
	60 mM	0.0599 mL	0.2994 mL	0.5989 mL	1.4971 mL
	80 mM	0.0449 mL	0.2246 mL	0.4491 mL	1.1228 mL
	100 mM	0.0359 mL	0.1797 mL	0.3593 mL	0.8983 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Pentoxifylline

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Pentoxifylline

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radiosensitizer Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product-like Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Antiviral Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Publications Citing Use of MedChemExpress (MCE) Pentoxifylline

Alle Phosphodiesterase (PDE) Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Pentoxifylline Related Classifications

HY-B0715 Related Classifications